GoodRx (NASDAQ:GDRX) Trading Up 5.8% – Time to Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) shot up 5.8% during trading on Friday . The company traded as high as $4.54 and last traded at $4.53. 660,285 shares were traded during trading, a decline of 39% from the average session volume of 1,087,214 shares. The stock had previously closed at $4.28.

Analyst Ratings Changes

GDRX has been the subject of a number of recent analyst reports. KeyCorp lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday. Barclays dropped their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Morgan Stanley reduced their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Mizuho assumed coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Finally, Citigroup reduced their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Stock Up 6.3 %

The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock’s fifty day simple moving average is $4.72 and its 200-day simple moving average is $6.56. The stock has a market cap of $1.73 billion, a P/E ratio of -151.67, a PEG ratio of 3.43 and a beta of 1.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in shares of GoodRx during the third quarter valued at $33,000. Plato Investment Management Ltd bought a new position in GoodRx in the 2nd quarter worth approximately $43,000. EP Wealth Advisors LLC acquired a new stake in GoodRx in the 3rd quarter valued at approximately $73,000. Sanctuary Advisors LLC acquired a new position in GoodRx during the 3rd quarter worth $85,000. Finally, Dark Forest Capital Management LP bought a new position in shares of GoodRx in the second quarter worth $86,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.